CAH Stock Recent News

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems' FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

DUBLIN, Ohio , Sept. 24, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2025 on November 1, prior to the opening of trading on the New York Stock Exchange.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Cardinal Health on Friday agreed to acquire Integrated Oncology Network, an independent community oncology network, for $1.12 billion in cash.

Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers  Accelerates the development of Navista oncology practice alliance , adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states DUBLIN, Ohio , Sept. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a definitive agreement to acquire Integrated Oncology Network (ION), a physician-led independent community oncology network, for $1.115B in cash.